Browse by Series:

Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

Howard Kaufman, MD
Published: Thursday, May 04, 2017



Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.
SELECTED
LANGUAGE
Slider Left
Slider Right


Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x